Stoke Therapeutics, Inc. (NASDAQ:STOK) CEO Edward M. Md Kaye Sells 6,786 Shares

Stoke Therapeutics, Inc. (NASDAQ:STOK) CEO Edward M. Md Kaye sold 6,786 shares of the firm’s stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $12.99, for a total transaction of $88,150.14. Following the completion of the sale, the chief executive officer now directly owns 61,885 shares in the company, valued at $803,886.15. This represents a 9.88 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Stoke Therapeutics Stock Performance

Shares of Stoke Therapeutics stock opened at $12.98 on Thursday. Stoke Therapeutics, Inc. has a 52-week low of $4.09 and a 52-week high of $17.58. The stock has a market capitalization of $687.55 million, a price-to-earnings ratio of -6.18 and a beta of 0.95. The company’s 50 day moving average price is $12.48 and its 200-day moving average price is $13.67.

Stoke Therapeutics (NASDAQ:STOK) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.05. The business had revenue of $4.89 million for the quarter, compared to analysts’ expectations of $3.46 million. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. As a group, equities research analysts forecast that Stoke Therapeutics, Inc. will post -2.03 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently weighed in on STOK. Leerink Partners began coverage on shares of Stoke Therapeutics in a research note on Monday, October 14th. They issued an “outperform” rating and a $18.00 target price on the stock. Leerink Partnrs raised shares of Stoke Therapeutics to a “strong-buy” rating in a research note on Friday, October 11th. Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 target price on shares of Stoke Therapeutics in a research note on Wednesday, November 6th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Stoke Therapeutics in a research note on Tuesday. Finally, HC Wainwright reiterated a “buy” rating and set a $35.00 price target on shares of Stoke Therapeutics in a research report on Wednesday, November 6th. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $20.83.

Hedge Funds Weigh In On Stoke Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Lynx1 Capital Management LP lifted its position in Stoke Therapeutics by 40.3% during the second quarter. Lynx1 Capital Management LP now owns 5,185,191 shares of the company’s stock valued at $70,052,000 after buying an additional 1,488,371 shares during the period. RTW Investments LP raised its position in Stoke Therapeutics by 10.1% in the 3rd quarter. RTW Investments LP now owns 4,652,285 shares of the company’s stock worth $57,177,000 after buying an additional 427,447 shares during the last quarter. State Street Corp raised its position in Stoke Therapeutics by 8.6% in the 3rd quarter. State Street Corp now owns 1,728,888 shares of the company’s stock worth $21,248,000 after buying an additional 137,145 shares during the last quarter. Assenagon Asset Management S.A. purchased a new position in Stoke Therapeutics in the 2nd quarter worth about $19,835,000. Finally, Healthcare of Ontario Pension Plan Trust Fund raised its position in Stoke Therapeutics by 426.1% in the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,387,200 shares of the company’s stock worth $18,741,000 after buying an additional 1,123,500 shares during the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.